Dr. Reddy’s Srikakulam Formulation Plant Gets One USFDA Observation

Dr. Reddy’s Laboratories has informed the bourses that the audit of its Formulations Srikakulam Plant (SEZ) Unit I, Andhra Pradesh has been completed by the US FDA on Friday. The company has been issued a Form 483 with one observation.

The company made the announcement after the market hours on Friday.

Dr. Reddy’s Laboratories closed at Rs 2677.10 per share on the BSE. It hit a high of Rs 2420 and a low of Rs 2632 during Friday’s trading session.

The stock has underperformed both BSE Sensex and BSE Healthcare over a period of one year. Its closest peers include Lupin and Sun Pharmaceutical Industries.

Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products.

or Quick Trial – 8962000225 ✔ 
or mail us here: info@ways2capital.com
or visit http://www.ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 ✔ 
Give a Missed Call for Free Trial - 09699997717 ✔